Using Hydroxyephedrine PET/CT to Diagnose Sympathetic Nervous System Diseases
Hydroxyephedrine PET/CT in Sympathetic Nervous System Diseases
Tianjin Medical University · NCT06951984
This study is testing a new type of imaging scan to see if it can help doctors better diagnose nerve-related diseases in adults with suspected or confirmed cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University (other) |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06951984 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 11C/18F-HED positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with various sympathetic nerve-related diseases. Participants, who are adults with suspected or diagnosed malignant tumors, undergo PET/CT scans to assess lesion uptake and quantify results using the maximum standard uptake value (SUVmax). The study aims to calculate the sensitivity, specificity, and accuracy of this imaging technique for better diagnosis and management of these conditions.
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 and older with suspected or newly diagnosed malignant tumors.
Not a fit: Patients with non-malignant lesions or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy for patients with sympathetic nervous system diseases, leading to improved treatment outcomes.
How similar studies have performed: Other studies have shown promising results using PET/CT imaging for similar diagnostic purposes, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Tianjin, Tianjin Municipality
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sympathetic Nervous System Diseases, Sympathetic Nervous Structure Injury, Sympathetic Nerve Injury, PET/CT, MRI, Hydroxyephedrine